ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO009

Complement Factor D, a New Predictor of Renal Allograft Dysfunction and Rejection?

Session Information

Category: Transplantation

  • 1702 Transplantation: Clinical and Translational

Authors

  • Daniel, Christoph, University Erlangen-Nürnberg, Erlangen, Germany
  • Bobka, Steffen, FAU Erlangen-Nürnberg, Erlangen, Germany
  • Buettner, Maike Julia, FAU Erlangen-Nürnberg, Erlangen, Germany
  • Amann, Kerstin U., FAU Erlangen-Nürnberg, Erlangen, Germany
Background

The complement system is part of innate immunity and thus important for graft function and survival. Here we focused on complement Factor D (CFD) that initiates alternative complement activation by cleavage of factor B. Triggers of CFD upregulation are unknown and it is unclear if CFD is already upregulated in zero-biopsies of transplanted kidneys. In addition, we assessed whether the alternative complement pathway is upregulated in the setting of delayed graft function.

Methods

CFD was investigated in renal zero- and corresponding transplant-biopsies of patients receiving a cadaveric kidney transplant using immunohistochemistry. Specimens were selected from patients with delayed graft function (DGF, n=12), T-cell mediated rejection (TCMR, n=10) and antibody mediated rejection (ABMR, n=8) and evaluated with regard to localization and degree of expression of CFD. Furthermore, renal complement factor D reactivity was correlated with renal function and transplantation conditions.

Results

CFD was located in different compartments of renal transplants. In 0-biopsies prominent CFD-staining was found in tubules in comparable amounts in all investigated groups. In contrast, glomerular CFD reactivity in 0-biopsies was at least 4-times lower compared to tubular staining but showed significant differences between groups. Highest glomerular CFD was detected in patients that later develop ABMR, being about 5-times higher compared to 0-biopsies from patients that developed DGF. Interestingly, CFD staining was prominent in glomerular, tubular and interstitial localization in post-transplant biopsies without clear differences between groups. The amount of glomerular CFD in 0-biopsies strongly correlated with renal changes including glomerulitis (r=0.628; p<0.001), chronic transplant glomerulopathy (r=0.659; p<0.001) and mesangial matrix expansion (r=0.771; p<0.001) in transplant-biopsies taken after at a later timepoint. Furthermore, donor serum creatinine correlated with tubular CFD in post-transplant biopsies (r=0.463; p=0.006).

Conclusion

CFD is upregulated in DGF and in antibody as well as T-cell mediated rejection compared to zero-biopsies. Our findings implicate CFD reactivity in 0-biopsies as a potentially useful predictor of pathophysiologic changes in transplanted kidneys in the post-transplantation time course.

Funding

  • Government Support - Non-U.S.